Voya Investment Management LLC Sells 4,597 Shares of Solventum Co. (NYSE:SOLV)

Voya Investment Management LLC lowered its holdings in Solventum Co. (NYSE:SOLV - Free Report) by 9.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 45,553 shares of the company's stock after selling 4,597 shares during the quarter. Voya Investment Management LLC's holdings in Solventum were worth $3,009,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. Modus Advisors LLC acquired a new stake in Solventum in the fourth quarter worth $25,000. Stonebridge Financial Group LLC bought a new stake in Solventum during the 4th quarter worth about $26,000. Crews Bank & Trust acquired a new position in shares of Solventum during the 4th quarter worth about $32,000. Synergy Asset Management LLC bought a new position in shares of Solventum in the 4th quarter valued at about $35,000. Finally, Spire Wealth Management bought a new stake in Solventum during the fourth quarter worth about $37,000.

Solventum Trading Down 1.9 %

Shares of NYSE SOLV traded down $1.28 during trading on Tuesday, reaching $65.61. The company had a trading volume of 1,144,918 shares, compared to its average volume of 1,280,707. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The stock has a market cap of $11.35 billion and a P/E ratio of 23.86. The company's fifty day moving average price is $71.25 and its 200-day moving average price is $71.42.

Analysts Set New Price Targets

Several brokerages have recently commented on SOLV. Morgan Stanley lifted their target price on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research note on Wednesday, March 5th. Piper Sandler reduced their price objective on shares of Solventum from $84.00 to $80.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Mizuho boosted their price target on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. Bank of America increased their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company upped their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $79.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.